Theratechnologies (THTX)
(Delayed Data from NSDQ)
$1.33 USD
+0.07 (5.56%)
Updated May 15, 2024 03:59 PM ET
After-Market: $1.33 0.00 (0.00%) 4:56 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
THTX 1.33 +0.07(5.56%)
Will THTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for THTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for THTX
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
THTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for THTX
Theratechnologies Shareholders Elect Directors, Appoint Auditors
Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies Announces New Board Chair
Theratechnologies Elects New Board Chair
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting